CoChat
Sign Up
Cited by 135Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease

Open access
Björkqvist, Maria, Ohlsson, Mattias, Minthon, Lennart, Hansson, Oskar·2012·PLoS ONE
DOI 10.1371/journal.pone.0029868PMC PMC3261152
Open this paper in CoChat — free accountOpen PDF

Abstract

There is an urgent need for biomarkers in plasma to identify Alzheimer's disease (AD). It has previously been shown that a signature of 18 plasma proteins can identify AD during pre-dementia and dementia stages (Ray et al, Nature Medicine, 2007). We quantified the same 18 proteins in plasma from 174 controls, 142 patients with AD, and 88 patients with other dementias. Only three of these proteins (EGF, PDGF-BB and MIP-1δ) differed significantly in plasma between controls and AD. The 18 proteins could classify patients with AD from controls with low diagnostic precision (area under the ROC curve was 63%). Moreover, they could not distinguish AD from other dementias. In conclusion, independent validation of results is important in explorative biomarker studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0029868

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recently, multiple studies have shown that reduced levels of platelet-derived growth factors (PDGFs) in plasma significantly correlate with mild cognitive impairment and have proposed PDGFs as a potential biomarker for AD.

    “Recently, multiple studies have shown that reduced levels of platelet-derived growth factors (PDGFs) in plasma significantly correlate with mild cognitive impairment and have proposed PDGFs as a potential biomarker for AD [95, 96].”

    From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [95]

    The Discussion (page unavailable) says an earlier study found reduced PDGF-BB in AD, but this paper found increased levels in AD cases instead. Its mention of mild cognitive impairment concerns an 18-protein panel, not a correlation with reduced PDGF levels; the Discussion also finds that panel unsuitable for clinical AD diagnosis. (LLM, conf=0.88)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 18

  1. [1]Blennow K de Leon MJ Zetterberg H 2006 Alzheimer's disease. Lancet 368 387 403 16876668
  2. [3]Jack CRJ Knopman DS Jagust WJ Shaw LM Aisen PS 2010 Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology 9 119 128 20083042 PMC2819840
  3. [6]Hampel H Frank R Broich K Teipel SJ Katz RG 2010 Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9 560 574 20592748
  4. [8]Hansson O Zetterberg H Buchhave P Londos E Blennow K 2006 Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5 228 234 16488378
  5. [10]Ray S Britschgi M Herbert C Takeda-Ushimara Boxer A 2007 Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13 1359 1362 17934472
  6. [12]McKhann G Drachman D Folstein M Folstein M Katzman R 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 939 944 6610841
  7. [13]Roman GC Tatemichi TK Erkinjuntti T Cummings JL Masde JC 1993 Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43 250 260 8094895
  8. [14]Erkinjuntti T Inzitari D Pantoni L Wallin A Scheltens P 2000 Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 59 23 30 10961414
  9. [15]McKeith IG Perry EK Perry RH 1999 Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 53 902 905 10496243
  10. [16]McKhann GM Albert MS Grossman M Miller B Dickson D 2001 Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58 1803 1809 11708987
  11. [17]Hosmer D Lemeshow S 1989 Applied logistic regression New York Wiley
  12. [19]Tibshirani R Hastie T Narasimhan B Chu G 2002 Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proceedings of the National Academy of Sciences of the United States of America 99 6567 72 12011421 PMC124443
  13. [21]Gòmez Ravetti M Moscato P 2008 Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease. PLoS ONE 3 e3111 18769539 PMC2518833
  14. [22]Soares HD Chen Y Sabbagh M Rohrer A Schrijvers E 2009 Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels. Annals of the New York Academy of Sciences 1180 56 67 19906261
  15. [23]Rocha de Paula M Gòmez Ravetti M Berretta R Moscato P 2011 Differences in abundances of cell-signalling proteins in blood reveal novel biomarkers for early detection of clinical alzheimer's disease. PLoS ONE 6 3 e17481 doi: 10.1371/journal.pone.0017481 21479255 PMC3063784 · DOI
  16. [24]Marksteiner J Kemmler G Weiss EM Knaus G Ullrich C 2011 Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiology of aging 3 539 40 PMC4311051 19395124
  17. [25]Knudsen LS Christensen IJ Lottenburger T Svendsen MN Nielsen L 2008 Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 13 59 78 17852075
  18. [26]Ioannidis JP Panagiotou OA 2011 Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subseuquent meta-analyses. JAMA 21 2200 10 21632484

Cited by

Sorted by citations

Authors
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O.
Affiliations
Lund University (SE)
Corresponding author
Björkqvist, Maria
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2012-01-18
Volume
7
Issue
1
Pages
e29868
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0029868
PMC
PMC3261152
OpenAlex
W2010418703
Cited by
135
References
6
Citations by year
2026: 3 · 2025: 7 · 2024: 5 · 2023: 12 · 2022: 6 · 2021: 14 · 2020: 10 · 2019: 6 · 2018: 10 · 2017: 8 · 2016: 10 · 2015: 10 · 2014: 13 · 2013: 14 · 2012: 7
FWCI
10.05
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion, other-oa)
Funders
  • Lunds Universitet
  • Vetenskapsrådet
  • Swedish Brain Power
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, plasma biomarkers, proteomic signatures, epidermal growth factor, PDGF-BB, dementia, diagnostic accuracy, biomarker validation, pre-dementia
MeSH terms
Becaplermin, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Dementia, Epidermal Growth Factor, Female, Humans, Middle Aged, Predictive Value of Tests, ROC Curve, Biomarkers, Macrophage Inflammatory Proteins, Chemokines, CC, Proto-Oncogene Proteins c-sis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review